Please login to the form below

Not currently logged in
Email:
Password:

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

The heart failure market is becoming increasingly competitive, with Jardiance’s positive results in the EMPEROR-Reduced trial competing with AstraZeneca’s heart failure drug Farxiga, which scored an FDA

Latest news

More from news
Approximately 14 fully matching, plus 44 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....